Fertility startup Inito has raised $29 million in Series B funding to expand its at-home health diagnostics platform and enable new types of at-home tests using AI-designed antibodies.
When the company launched its first fertility monitor in 2021, its goal was to enable quantitative testing of fertility hormones at home.
Standard home ovulation tests predict fertile days by tracking estrogen and luteinizing hormone (LH), but they do not measure the progesterone metabolite PdG, the hormone that confirms ovulation. Inito allows women to measure estrogen, LH, progesterone (PdG), and FSH (follicle stimulating hormone) with one test strip. Inito's AI model interprets these levels to reveal reproductive hormone patterns, track fertile days, and confirm ovulation.
Fast forward to today, and the startup has become a popular choice for women looking to track their fertility hormones, having analyzed over 30 million fertility hormone data points since 2021.
The startup is currently working on evolving Inito from a fertility tracker to a broader hormonal and home health diagnostic platform, further reinforcing its belief that healthcare should start at home.
Inito is using the new funding to invest in and develop AI-engineered antibodies, which it says will enable the development of new types of tests and improve the accuracy of existing tests.
To explain, when you take a test in a lab or at home, antibodies bind to target molecules (such as estrogen or testosterone) and generate a signal. Traditional antibodies are grown in animals and then manually screened in the lab, which can be a time-consuming and expensive process. Traditional antibodies also lack the sensitivity to test for a large number of biomarkers at home.
tech crunch event
san francisco
|
October 13-15, 2026
Inito says AI-designed antibodies will change the game. Instead of “growing” antibodies in animals, we can treat antibodies like software.
“We predict how proteins will fold in 3D, use AI to design synthetic antibodies, and virtually test millions of variants before creating a single variant in the lab,” Inito co-founder and CTO Varun Venkatesan explained in an email. “This produces antibodies that are much more sensitive, consistent, and stable than those developed using traditional methods.”
For Inito, this enables the next generation of at-home testing. Venkatesan said the company is already using these techniques in research and development and is seeing promising results in the wet lab.
“The real vision is bigger than adding new tests,” said Aayush Rai, co-founder and CEO of Inito. “The end goal is to completely redefine diagnostics. If you want to understand what's going on inside your body at every life stage and health need, you shouldn't be limited by clinic appointments, test schedules, or rigid testing systems. You should be able to measure, track, and gain insight about your body from home with lab-level confidence.”
Inito wants to expand its vision beyond the platform it's “trying to envision.” Its leaders and apps will soon ramp up tests for pregnancy, menopause, and broader home health monitoring.
“Our long-term roadmap goes far beyond fertility,” Lai said. “We are building towards a platform that can measure and interpret the full range of hormones that shape lifelong health. A wide range of endocrine markers such as pregnancy progression, menopause, and testosterone are all powered by the AI antibodies and imaging that sets Inito apart today.”
The company will use a portion of the funding to scale up manufacturing and grow globally to meet growing demand across the U.S. and in new international markets.
Inito's latest funding round was led by Bertelsmann India Investments and Fireside Ventures. This investment brings Inito's total funding to approximately $45 million. The company has raised $6 million led by Fireside Ventures and $9 million from Y Combinator, former Nurx CEO Varsha Rao, and more than a dozen doctors and family offices.
